Molecular Multispeciality Hospitals Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 6.66 Cr
as on 22-12-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 22-12-2024
- Revenue %
(FY 2021)
- Ebitda
- Net Worth
- Total Assets 5.82%
(FY 2021)
About Molecular Multispeciality Hospitals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 6.66 Cr.
The company currently has active open charges totaling ₹3.00 Cr.
Kizhakkebhagathu Joy, Chirayath Varkey, Mibu Jose, and Two other members serve as directors at the Company.
- CIN/LLPIN
U85110KL2013PTC033263
- Company No.
033263
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Molecular Multispeciality Hospitals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kizhakkebhagathu Joy  | Managing Director | 07-Feb-2013 | Current |
| Chirayath Varkey | Managing Director | 07-Feb-2013 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mibu Jose | Director | 07-Feb-2013 | Current |
| Mathew Kattukkaran | Director | 07-Feb-2013 | Current |
| Methale Kunhi | Director | 07-Feb-2013 | Current |
Financial Performance of Molecular Multispeciality Hospitals.
Molecular Multispeciality Hospitals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Molecular Multispeciality Hospitals?
In 2021, Molecular Multispeciality Hospitals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Apr 2016 | ₹3.00 Cr | Open |
How Many Employees Work at Molecular Multispeciality Hospitals?
Unlock and access historical data on people associated with Molecular Multispeciality Hospitals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Molecular Multispeciality Hospitals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Molecular Multispeciality Hospitals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
